Cytokinetics Inc. (CYTK)
Cytokinetics Inc. (CYTK) is a biopharmaceutical company focused on developing muscle biology-based therapies for debilitating diseases. The company's key areas of interest include treatments for conditions such as amyotrophic lateral sclerosis (ALS), heart failure, and other muscle-related disorders. Cytokinetics leverages its expertise in muscle contractility and cytoskeletal proteins to discover, develop, and commercialize innovative therapeutic agents.
Company News
Cytokinetics will report its third quarter 2025 financial results on November 5, 2025, followed by a conference call discussing financial performance and business updates, focusing on its cardiovascular drug development pipeline.
The FDA has extended the PDUFA action date for Cytokinetics' new drug application for aficamten, an experimental heart drug, by three months to allow for a full review of the company's proposed Risk Evaluation and Mitigation Strategy (REMS).
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
These two biotech stocks could be big winners in the years ahead.